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Summary
 
Although recent studies have indicated that the major histocompatibility complex–like, 
 
b
 
2-micro-
globulin–associated CD1 molecules might function to present a novel chemical class of anti-
gens, lipids and glycolipids, to 
 
a
 
/
 
b
 
 T cells, little is known about the T cell subsets that interact
with CD1. A subset of CD1d-autoreactive, natural killer (NK)1.1 receptor–expressing 
 
a
 
/
 
b
 
 T
cells has recently been identified. These cells, which include both CD4
 
2
 
CD8
 
2
 
 and CD4
 
1
 
 T
cells, preferentially use an invariant V
 
a
 
14-J
 
a
 
281 T cell receptor (TCR) 
 
a
 
 chain paired with a
V
 
b
 
8 TCR 
 
b
 
 chain in mice, or the homologous V
 
a
 
24-J
 
a
 
Q/V
 
b
 
11 in humans. This cell subset
can explosively release key cytokines such as interleukin (IL)-4 and interferon (IFN)-
 
g
 
 upon
TCR engagement and may regulate a variety of infectious and autoimmune conditions. Here,
we report the existence of a second subset of CD1d-restricted CD4
 
1
 
 T cells that do not express
the NK1.1 receptor or the V
 
a
 
14 TCR. Like the V
 
a
 
14
 
1
 
 NK1.1
 
1
 
 T cells, these T cells exhibit
a high frequency of autoreactivity to CD1d, use a restricted albeit distinct set of TCR gene
families, and contribute to the early burst of IL-4 and IFN-
 
g
 
 induced by intravenous injection
of anti-CD3. However, the V
 
a
 
14
 
1
 
 NK1.1
 
1
 
 and V
 
a
 
14
 
2
 
 NK1.1
 
2
 
 T cells differ markedly in
their requirements for self-antigen presentation. Antigen presentation to the V
 
a
 
14
 
1
 
 NK1.1
 
1
 
cells requires endosomal targeting of CD1d through a tail-encoded tyrosine-based motif,
whereas antigen presentation to the V
 
a
 
14
 
2
 
 NK1.1
 
2
 
 cells does not. These experiments suggest
the existence of two phenotypically different subsets of CD1d-restricted T cells that survey self-
antigens loaded in distinct cellular compartments.
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C
 
lassical MHC class I and class II molecules in verte-
brates capture pathogen-derived peptides in the en-
doplasmic reticulum or in the endosomal compartment,
and present them on the cell surface for recognition by
CD8
 
1
 
 or CD4
 
1
 
 
 
a
 
/
 
b
 
 T lymphocytes, respectively (1). In
contrast, CD1 molecules, a family of MHC-like, non–
MHC-encoded molecules, seem to present a novel anti-
genic universe, made of lipids rather than peptides, to T
cells (2). Human CD1b and CD1c molecules can present
various lipid and glycolipid components of mycobacterial
cell walls (3–5). CD1d, a conserved isotype that is ex-
pressed by all mammals studied to date, and the only one
that is expressed by mice and rats, may also bind various
glycolipids, including glycosyl phosphatidyl inositols (6)
and glycosylated ceramides (7).
Although little is known about the frequency and phe-
notype of T cells that use CD1 as a presenting molecule, or
about the antigen presentation pathways associated with
CD1, several observations suggest that they differ from
those defined in the classical MHC system. In humans, a
few CD1b- and CD1c-restricted T cell lines have been re-
ported. Most of them have an unusual CD4/CD8 double
negative phenotype (3–5), while some are CD8
 
1
 
 (8). Their
recognition of mycobacterial lipid antigens depends on a
tyrosine-based motif encoded in the cytoplasmic tail of
CD1b itself that targets CD1b to the endosome, a different
mechanism of endosomal trafficking than that of the MHC
class II pathway (9, 10). CD1d, the only CD1 isotype in
mice, interacts with a prominent subset of CD1d-restricted
T cells that has been identified in vivo on the basis of its
unique phenotype and functional properties. This subset
comprises the NK1.1 receptor–expressing 
 
a
 
/
 
b
 
 T cells (NK
T cells) that preferentially use an invariant V
 
a
 
14-J
 
a
 
281
TCR 
 
a
 
 chain paired with a V
 
b
 
8 TCR 
 
b
 
 chain in mice 
104
 
Two Pathways of Antigen Presentation by CD1
 
(11, 12) or the homologous V
 
a
 
24-J
 
a
 
Q/V
 
b
 
11 in humans
(11, 13, 14). This cell subset, which includes both double
negative and CD4 T cells, accounts for 15% of mature thy-
mocytes, 5% of spleen T cells, and 30% of liver T cells. The
unusual functional properties of these NK T cells (15),
which include their ability to explosively release key cyto-
kines such as IL-4 and IFN-
 
g
 
 upon TCR engagement, are
thought to be the basis for their role in various intracellular
infections (16, 17), in tumor rejection (18), and in autoim-
mune diseases (19, 20). A large fraction of these cells can be
shown to be autoreactive to CD1d-expressing cells (12).
Thus, a recent report showing that alpha galactosyl ceramide,
a component of marine sponges, can specifically stimulate
most V
 
a
 
14-J
 
a
 
281/V
 
b
 
8 T cells in a CD1d-restricted fash-
ion (7) suggests that these cells might survey a single, yet
unidentified family of self-glycolipids with homology to al-
pha galactosyl ceramide. There have been reports of other
CD1d-autoreactive T cell hybridomas that do not use
V
 
a
 
14 TCRs (11, 12, 21), but the phenotype and the func-
tional properties of their precursor cell type have not been
characterized in vivo. Therefore, we asked whether these
hybridomas belonged to the NK1.1
 
1
 
 subset or were per-
haps a window into a new T cell subset.
Here, we report the existence of a novel, prominent
subset of CD1d-restricted T cells that do not express the
NK1.1 receptor or the V
 
a
 
14 TCR. Like V
 
a
 
14
 
1
 
 NK1.1
 
1
 
T cells, these T cells exhibit a high frequency of autoreac-
tivity to CD1d, use a restricted set of TCR gene families,
and contribute to the early burst of IL-4 and IFN-
 
g
 
 in-
duced by intravenous injection of anti-CD3. However,
V
 
a
 
14
 
1
 
 NK1.1
 
1
 
 and V
 
a
 
14
 
2
 
 NK1.1
 
2
 
 T cells differ mark-
edly in their requirements for self-antigen presentation.
V
 
a
 
14
 
1
 
 NK1.1
 
1
 
 cells require endosomal targeting of CD1d
through a tail-encoded tyrosine-based motif for antigen
recognition, whereas V
 
a
 
14
 
2
 
 NK1.1
 
2
 
 T cells do not. Alto-
gether, these experiments suggest that there are two phe-
notypically different subsets of CD1d-restricted T cells that
survey antigens loaded in distinct cellular compartments.
These results have significant implications for the antigen
presenting functions of CD1 molecules.
 
Materials and Methods
 
Mice.
 
C57BL/6 and C57BL/6 IA
 
b
 
b
 
2
 
/
 
2
 
 (MHC II
 
2
 
/
 
2
 
) mice
were obtained from Taconic Farms. V
 
a
 
14-J
 
a
 
281 transgenic mice
in a C57BL/6 or C57BL/6 C
 
a
 
 knockout background were de-
scribed previously (22). All mice were raised in a specific patho-
gen–free barrier environment at Princeton University, according
to institutional animal care and use guidelines.
 
T Cell Subset Staining and Purification.
 
Pooled splenocytes ob-
tained from 10 C57BL/6.MHC II
 
2
 
/
 
2
 
 mice were enriched in
CD4 cells by incubation with 53.6.7, an anti-CD8 mAb followed
by panning onto goat anti–rat/mouse Ig (Southern Biotechnolo-
gies)-coated plates. After staining with anti-CD4–FITC and anti-
NK1.1–PE (PharMingen), NK1.1-positive and -negative CD4
 
1
 
cells were FACS
 
®
 
 sorted with a 
 
.
 
95% purity.
 
In Vitro T Cell Stimulation Assay.
 
T cells were cultured for 18 h
in the presence of CD1d-expressing cells (5 
 
3 
 
10
 
4
 
 responders and
5 
 
3 
 
10
 
4
 
 transfectant or 5 
 
3 
 
10
 
5
 
 thymocyte or splenocyte stimula-
 
tors, unless otherwise stated) in 100 
 
m
 
l of a 1:1 mixture of Click’s
medium and RPMI (Biofluids) enriched with 10% heat-inacti-
vated FCS, glutamine, antibiotics, and 5 
 
3 
 
10
 
2
 
5
 
 2-ME. IL-2 or
IL-4 released in the supernatant was measured using the CTLL or
CT4S bioassays, respectively, as described (23).
 
T Cell Hybridoma Generation.
 
Purified T cell subsets were
cultured for 5 d with anti-CD3 and IL-2 and fused with
BW5147
 
ab
 
2
 
 as described (11). V
 
a
 
14-J
 
a
 
281–positive hybrido-
mas were identified by PCR (11). CD1d-autoreactive hybrido-
mas specifically secreted IL-2 (as well as IL-4) upon culture with
CD1d-transfected RBL or C57SV cells but not with untrans-
fected cells, or with a mixture of thymocytes and splenocytes
from 129 but not 129.CD1
 
2
 
/
 
2
 
 mice.
 
Competitive Reverse Transcription PCR Quantification of Cytokine
mRNA.
 
Messenger RNA was purified from 10
 
5
 
 FACS
 
®-sorted
cells using the RNeasy Mini Kit (QIAGEN), reverse transcribed,
and PCR amplified using IL-4, IFN-g, and hypoxanthine phos-
phoribosyl transferase (HPRT)1-specific primers in the presence
of titrated amounts of competitor plasmids as described (24).
TCR Gene Sequencing. Reverse transcription (RT)-PCR,
primers, and methods were as described previously (11).
CD1d Tail–mutant Constructs and Transfectants. Complemen-
tary DNA for CD1-TD was generated by PCR using full-length
CD1d cDNA (25) as template. First, primers S3 (59-CCCTGG-
GAATGCTTCGG-39) and tR2 (59-GGCAGGTGTAAGGAA-
GAGTCATCTCCTTCTCCAGATATAGTA-39) were used to
amplify the 600-bp fragment A, and primers tNotI (59-AAAA-
AGCGGCCGCGCAGGTACGCACATTTGCAGTT-39) and tF2
(59-TACTATATCTGGAGAAGGAGATGACTCTTCCTTA-
CACCTGCC-39) were used to amplify the 240-bp fragment B.
The sequences of the tR2 and tF2 primers are complementary to
each other. Fragments A and B were then used together as tem-
plates to amplify the chimeric PCR fragment C using the S3 and
tNotI primers. To generate the CD1-TD plasmid Tdel2, frag-
ment C was digested by BstEII and NotI and then subcloned into
pCD113 (25) to replace its wild-type counterpart CD1-WT. The
cDNA for Y332F was generated by PCR using pCD113 as tem-
plate. Primers used were t-F332 (59-GGAGAAGGAGAAGC-
GCTTTTCAAGACATCCGG-39) and CD1-R (59-AAACTC-
GAGGCAGGTACGCACATTTGCAGT-39). A single mutation
introduced in the t-F332 primer is underlined. The amplifed
270-bp fragment was digested with Eco47III and XhoI and then
subcloned into pCD113 to replace its wild-type counterpart. The
sequence mutations were confirmed by sequencing. Plasmids
(pCD113, Tdel2, and Y332F) were linearized by PvuI and XmnI
before transfection. Transfection and selection of stable transfec-
tants were as described (25).
Confocal Microscope Analysis. Labelings were performed essen-
tially as described (26). Cells washed twice in cold PBS were
fixed in 4% paraformaldehyde and 4% sucrose in PBS for 20 min
at room temperature. Subsequent steps were performed at room
temperature. After quenching for 20 min in 50 mM NH4Cl in
PBS, the cells were washed once in PBS and permeabilized for 5
min in 0.05% saponin in the buffer used for washing. Cells were
then incubated with anti–LAMP-1 (PharMingen) in the perme-
abilizing buffer for 45 min. After two washes in this permeabiliz-
ing buffer, the presence of anti–LAMP-1 antibodies was revealed
by incubating the cells for 45 min in permeabilizing buffer con-
taining Rhodamine-labeled rabbit secondary antibodies (1:50;
DAKO). After two washes in permeabilizing buffer, the cells
1Abbreviations used in this paper: HPRT, hypoxanthine ribosyl transferase;
mfi, mean fluorescent intensity; RT, reverse transcriptase.105 Chiu et al.
were incubated for 45 min with FITC-labeled rat anti-CD1d
mAb 19G11 (27). After three washes in permeabilizing buffer and
one wash in PBS, the cells were mounted in 100 mg/ml 1,4 dia-
cylbicyclo (2.2.2) octane (Dabco; Sigma Chemical Co.), 100 mg/
ml moviol (Calbiochem Corp.), 25% (vol/vol) glycerol, 100 mM
Tris-HCl, pH 8.5. The samples were examined under an LSM
510 confocal microscope attached to an axiovert microscope
equipped with an argon and a helium-neon laser (Carl Zeiss,
Inc.). The Rhodamine and FITC emissions were recorded se-
quentially. Optical sections were recorded with a 633 lens and a
pinhole aperture such that the thickness of the sections was z0.7
mm. No immunofluorescence staining was observed when sec-
ond antibodies were used without the first antibody or with an
irrelevant first antibody.
Results
Two Subsets of CD1d-restricted T Cells. To determine
whether there are CD1d-restricted CD4 cell subsets other
than the NK T cell subset, we reexamined the residual
CD4 cell population found in C57BL/6 mice bearing a tar-
geted mutation of MHC class II (IAbb2/2, referred to as
MHC II2/2). Fig. 1 shows that the residual 2 or 3% CD41
cells in MHC II2/2 mice could be divided into CD41
NK1.11 (one third) and CD41NK1.12 (two thirds) cells,
as reported previously (21, 28–30). To examine these cells at
the single cell level, we generated separate panels of T cell
hybridomas from these sorted cell subsets. The hybrids
were screened for autoreactivity to CD1d-transfected cells
or to cells that naturally express CD1d, such as thymocytes
and splenocytes, and for expression of the canonical Va14-
Ja281 TCR a chain. Significant numbers of CD1d-
autoreactive cells were found in both NK1.11 (27%) and
NK1.12 (32%)–derived subsets (Fig. 1). Most of the hy-
brids derived from NK1.11 cells used the Va14-Ja281
TCR a chain (81%), as expected, whereas most of those
derived from NK1.12 cells (86%) did not. Though the
NK1.12 CD1d-autoreactive subset does not use the ca-
nonical Va14-Ja281 TCR, it is nevertheless not a highly
heterogeneous set but expresses a rather restricted set of
TCR genes. For example, out of 13 such Va14-negative
CD1d-autoreactive hybridomas collected in several inde-
pendent fusion experiments and used in the experiments
depicted below in Fig. 4, 5 used Va8, and 3 of them, de-
rived from 2 different mice, had the Va8 gene rearranged
to the same Ja19 segment. Studies in progress on larger
panels of hybridomas confirm that CD41NK1.12 cells
have a biased use of Va gene families (data not shown). In
addition, a majority of the Va14-negative CD1d-autoreac-
tive hybrids (9 out of 13), like the Va14-positive hybrids
(11), used Vb8.2 (see legend to Fig. 4) with diverse junc-
tional regions (not shown). Thus, the results demonstrate
the existence of a second novel, phenotypically distinct set
of CD1d-restricted T cells that are NK1.12, use limited
sets of TCRs, are autoreactive to CD1d, and whose fre-
quency is comparable to that of Va141 NK1.11 cells.
Evidence for an Endosomal Pathway of Antigen Presentation
by CD1d to Va141 T Cell Hybridomas. The use of a lim-
ited set of TCR families by both sets of CD1d-autoreactive
cells suggests that they might recognize a limited number of
CD1d-associated self-antigens. To examine the origin of
self-molecules potentially presented by CD1d, we took ad-
vantage of the existence of a targeting motif in the cyto-
plasmic tail of CD1d that gives it access to the endosomal
compartment (9, 31). We constructed a tail-deleted variant
(CD1-TD) lacking the SAYQDIR COOH-terminal end
of the cytoplasmic tail which contains the endosomal tar-
geting motif (underlined), and generated stable transfectants
expressing CD1-TD or the wild-type CD1 (CD1-WT) us-
ing two different cell lines, mouse C57SV fibroblasts (32)
and rat RBL basophils (33). CD1-TD was well expressed
on the plasma membrane (Fig. 2 a) in a highly glycosylated
form similar to that of CD1-WT (not shown). Fig. 2 b
shows that CD1-WT exhibited a prominent intracytoplas-
mic distribution with a diffuse vesicular pattern that colo-
calized extensively with LAMP-1, indicating that a signifi-
cant fraction of the CD1 molecules pass through a late
endosome/lysosome location. A similar distribution was
found in BCL-1, a B cell line that naturally expresses CD1d
(not shown). In contrast, most LAMP-1–positive vesicules
were devoid of CD1d in CD1-TD–transfected cells, de-
spite the matched expression levels of surface CD1d. These
results, shown in Fig. 2 for C57SV, a mouse fibroblast cell
line, are identical to those recently reported for a mouse B
cell line, A20, transfected with CD1-WT or CD1-TD
(31), and are similar to those established previously in the
human CD1b system (9).
To determine whether the CD1d molecules trafficking
through the endosome pick up a distinct set of self-anti-
gens, we compared the ability of CD1-WT and CD1-TD
transfectants to stimulate CD1d-autoreactive T cells. To
achieve a dose titration of the CD1d molecules, we used
multiple rounds of FACS® sorting to select several sublines
expressing different surface levels of CD1-WT or CD1-
TD. Fig. 3 shows that DN32.D3, a canonical Va14-
Ja281/Vb8 hybridoma, responded 10-fold less well to
CD1-TD than to CD1-WT, whether the CD1d molecule
was expressed by rat RBL basophils or by mouse C57SV fi-
broblasts. In contrast, 1C8.DC1, a Va14-negative hybri-
doma, showed identical responses to CD1-WT and CD1-
TD over a wide range of surface concentrations, indicating
that the CD1d-associated antigens recognized by 1C8.DC1
were essentially unaffected by the drastic changes in intra-
Figure 1. Two subsets of
CD1d-autoreactive T cells. Re-
sidual CD41 cells in the spleen
of MHC II2/2 mice were en-
riched by panning against CD8
and Ig, sorted into NK1.1-posi-
tive and -negative subsets, acti-
vated for 5 d with anti-CD3 and
IL-2 in vitro, and fused with
BW5147ab2 to obtain T hybri-
domas. Individual hybridomas
were screened for CD1d-autore-
activity and for Va14-Ja281 re-
arrangement.106 Two Pathways of Antigen Presentation by CD1
cellular trafficking associated with the tail truncation, and
therefore that they are most likely loaded in the secretory
pathway. Again, identical results were obtained for both
C57SV and RBL transfectants, as shown in Fig. 3, left and
right, respectively, and confirmed in independent transfec-
tion experiments. An additional mutant of CD1d, CD1-
Phe, which contains a Tyr to Phe mutation in the cytoplas-
mic tail motif, reproduced the CD1-TD phenotype (not
shown, and see Table I below).
These results suggested the existence of two separate
pathways of antigen presentation by CD1d, one dependent
on and one independent of endosomal trafficking, and there-
fore the existence of two separate pools of self-antigens
loaded in distinct intracellular compartments. To test whether
the differences in recognition exhibited by DN32.D3 and
1C8.DC1 were characteristic of their representative subsets,
we tested an extended panel of CD1d-autoreactive T cell hy-
bridomas generated from normal or MHC II2/2 spleno-
cytes or thymocytes over the course of 3 yr in seven fusion
experiments. Fig. 4 is a compilation of several experiments
comparing their recognition of C57SV and RBL transfec-
tants expressing matched levels of CD1-TD and CD1-WT.
We found that none of the 13 Va14-negative hybridomas
discriminated between CD1-WT and CD1-TD, whereas
10 out of 14 (71%) Va14-positive hybridomas clearly did,
exhibiting a 3–15-fold impaired recognition of CD1-TD.
These patterns of recognition of CD1-WT and CD1-TD
suggest that there is a systematic difference between the
two T cell subsets in their antigen presentation require-
ments.
Fresh NK1.11 Va141 T Cells Require Endosomal Traf-
ficking of CD1d for Efficient Recognition. A few (4 out of
14) Va14-positive hybridomas were able to recognize
CD1-TD as well as CD1-WT, possibly because of residual
access of CD1-TD to the endosomal compartment, or be-
cause they crossreacted with other antigens. To assay a
larger population of Va14-positive T cells, and to rule out
potential biases associated with studies of in vitro–derived
hybridomas, we studied cells from a transgenic mouse
where the invariant Va14-Ja281 TCR a chain is ex-
pressed by all T cells, in association with endogenous, poly-
clonal TCR b chains (22). These T cells constitute a fresh
polyclonal population of Va14-Ja281–positive CD1d-
autoreactive T cells. Table I shows that Va14-Ja281 trans-
genic thymocytes responded strongly to CD1-WT– and
poorly to CD1-TD–transfected cells. The response of 5 3
104 transgenic cells to RBL.CD1-TD was much lower
than the response of 104 cells to RBL.CD1-WT, suggest-
ing that .80% of fresh Va14-positive cells specifically see
endosomally loaded antigens. The control Va14-negative
T cell hybridoma 1C8.DC1 used in this experiment re-
sponded equally to both. We next compared fresh NK1.11
and NK1.12 CD41 cells purified from the spleens of MHC
Figure 2. Cellular localization of CD1-WT and CD1-TD. (a) Mouse
C57SV fibroblasts were stably transfected with CD1-WT or CD1-TD
cDNA and selected by flow cytometry after staining with anti-CD1d
19G11-PE to express matched surface levels of CD1. (b) Representative
medial optical cuts of CD1-WT (left) or CD1-TD (right) expressing
C57SV cells double stained with anti-CD1d (FITC, top) and anti–
LAMP-1 (Rhodamine, bottom) demonstrate that most LAMP-1–positive
intracytoplasmic vesicules contain CD1-WT but not CD1-TD.
Figure 3. CD1-WT and CD1-TD are differently recognized by some
T cell hybridomas. DN32.D3, a Va14-Ja281–positive hybridoma, and
1C8.DC1, a Va14-negative hybridoma, were stimulated with CD1-WT
(filled squares) or CD1-TD (open squares)–transfected RBL (left) or
C57SV (right) cells, and the IL-2 release was measured using the CTLL
bioassay. Stable transfectants were FACS® selected for expression of a
range of surface concentrations of CD1d. Surface levels of CD1d were es-
timated at saturation of staining antibody on a fluorescent bead–calibrated
FACScan® (Becton Dickinson) and were proportional to the mean fluo-
rescent intensity (mfi). Thus, the top left panel shows that RBL.CD1-TD
expressing 239 mfi of CD1d was less stimulatory for DN32.D3 than
RBL.CD1-WT expressing six times less CD1d (mfi 5 43), whereas both
forms of CD1d stimulated 1C8.DC1 equally efficiently (bottom left).
Similar results with C57SV transfectants are shown on the right. Hybri-
domas stimulated with untransfected C57SV or RBL cells did not secrete
detectable IL-2 (,0.2 U/ml).107 Chiu et al.
II2/2 mice. Although these are not pure populations of
Va14-positive and -negative cells, they are significantly bi-
ased, containing 81 vs. 14% Va14-positive cells, respec-
tively (see Fig. 1). Here again, the NK1.11 (Va14-rich)
subset responded much more strongly to CD1-WT than to
CD1-Phe (or CD1-TD, not shown), whereas the NK1.12
(Va14-poor) subset responded well to both (Table I).
In a recent study, a single hybridoma out of two Va141
hybrids tested was found to react less well to CD1-TD than
to CD1-WT (31). The reaction patterns of our 27 hybri-
domas as well as those of fresh Va14 transgenic and fresh
NK1.11 and NK1.12 cells conclusively demonstrate that
the ability to discriminate CD1-TD from CD1-WT is the
common, characteristic pattern of the Va14 T cell subset.
Both NK1.11 and NK1.12 T Cells Contribute to the Early
Burst of IL-4 Induced by Anti-CD3 Injection In Vivo. A hall-
mark of NK T cells is their extraordinary ability to synthe-
size and secrete large amounts of cytokines, especially IL-4,
at peak levels very quickly after anti-CD3 injection in vivo,
a unique property that is likely to influence the outcome of
the responses in which they are involved (22, 34). To de-
termine whether CD41NK1.12 cells can contribute to this
early cytokine burst, we purified CD41NK1.12 and CD41
NK1.11 splenocytes 1.5 h after intravenous injection of 1
mg of 2C11 anti-CD3 antibody to MHC II2/2 mice, and
measured their IL-4 and IFN-g mRNA using a competi-
tive RT-PCR procedure (24). Fig. 5 shows that both sub-
sets contributed significantly to the early cytokine burst, al-
though NK1.11 T cells tended to produce two to three
times more IL-4 and IFN-g mRNA than NK1.12 T cells
within this short time-frame. In conventional in vitro mi-
togen stimulation assays, both subsets released the same
amount of both IL-4 and IFN-g proteins after a period of
48 h (not shown). Thus, we conclude that both subsets can
produce IL-4 and IFN-g upon primary stimulation, al-
though the kinetics of in vivo production may be faster for
NK T cells.
Discussion
We have identified the in vivo counterpart of the non–
Va14-expressing CD1d-autoreactive a/b T cell hybrido-
mas reported previously by several laboratories, and
showed that they belong to a novel subset of T cells that
shares some characteristics with the Va141NK1.11 T cells
but differs in many others. Like Va14-positive NK T cells,
these T cells exhibit a high frequency of autoreactivity to
CD1d, use restricted families of TCRs, and contribute to
the early burst of IL-4 and IFN-g induced by intravenous
injection of anti-CD3. However, they do not express the
NK1.1 receptor. In addition, they recognize different sub-
sets of CD1d molecules. We showed using a large panel of
hybridomas as well as polyclonal fresh populations of
Va14-positive and -negative T cells that the Va141
NK1.11 T cells require endosomal targeting of CD1d
through a tail-encoded tyrosine-based motif for recogni-
tion of CD1d, whereas the newly discovered Va142
NK1.12 T cells do not. This dichotomy between NK1.1-
positive and -negative T cells is independent of the expres-
sion of NK1.1, because NK T cell–derived hybridomas fail
to express NK1.1 (35; and data not shown). Altogether,
these experiments clearly establish that there are two phe-
notypically different subsets of CD1d-restricted T cells that
survey antigens loaded in distinct cellular compartments.
The results imply that CD1d may load self-antigens in
the two cellular compartments that are sampled separately
by the classical MHC class I and class II molecules. To sam-
ple the endosome, it uses an endosomal targeting motif
Figure 4. Most Va14-Ja281–positive T cell hybridomas do not effi-
ciently recognize CD1-TD. Compilation of multiple experiments per-
formed with 14 Va14-Ja281–positive and 13 Va14-Ja281–negative hy-
bridomas stimulated with RBL (filled circles) or C57SV (open circles)
transfectants. Results are expressed as the ratio of IL-2 production elicited
by cells expressing CD1-TD over that elicited by cells expressing similar
levels of CD1-WT. Hybridomas stimulated with untransfected C57SV or
RBL cells did not secrete detectable IL-2. The hybridomas were obtained
from a total of seven independent fusions of B6 CD44hiHSAlo thymocytes
(431.A11, DN32.D3, DN32.F3); B6.MHC II2/2 HSAloCD41 thy-
mocytes (TB.A7, TC.B11); B6.MHC II2/2 NK1.11CD41 thymocytes
(P4, P6, P9, P12, P17, P41, P72); B6.MHC II2/2 NK1.11 (S2P4, S2P16,
S2P23, S2P26, S2P29) and NK1.12 (S2M6, S2M7, S2M9, S2M10, S2M16)
CD41 splenocytes; B6.MHC II2/2 CD82 splenocytes (1C8.DC1); and
B6.Va14-Ja281 Tg Ca2/2 splenocytes (Va14.C7, Va14.A2, Va14.D21).
Va-Ja gene usage is indicated. All hybridomas used Vb8.2 TCR b chains
with the exception of P17 (Vb14), 1C8.DC1 (ND), S2M7 (Vb11),
S2P16 (Vb4), and P72 (ND).108 Two Pathways of Antigen Presentation by CD1
without which it can efficiently only sample the secretory
pathway. In support of the existence of a secretory pathway
of antigen loading is the recent report that a soluble, secre-
tory form of CD1d could be loaded with endogenous cel-
lular glycosyl phosphatidyl inositols (6). The existence of a
second, endosomal pathway has also been previously sug-
gested by the finding that presentation of alpha galactosyl
ceramide, a mimic of the self-antigen recognized by Va14
cells, is chloroquine dependent (7). As suggested (9), CD1d
may differ from MHC class II in that it might reach the cell
surface first and only secondarily be internalized, using its
tail-encoded tyrosine-based motif to access the endosome,
load new antigens, and recycle to the cell surface. Indeed,
experiments in progress in our laboratory indicate that the
rate of internalization of CD1-TD is significantly reduced
compared with that of CD1-WT (data not shown)
Therefore, like MHC class I and class II–restricted CD8
and CD4 T cells, CD1d-restricted Va14-negative and
Va14-positive cells may survey different pathways of anti-
gen presentation. This dichotomy is reinforced by the dis-
tinct phenotypes of the two subsets, in particular with
respect to the expression of the NK1.1 receptor. The
emerging picture is that CD1d-restricted T cells constitute
at least two subsets of a/b T lymphocytes, comparable in
numbers to the NK cells (on the order of 1–20% of the
lymphocyte compartment in various tissues), that are par-
ticularly enriched in some tissues, such as the liver, spleen,
and bone marrow, and that use a limited number of TCRs
to focus on a limited number of distinct self- and foreign
antigens. Although the self-antigens recognized by the two
subsets of CD1d-restricted T cells described here remain to
be characterized, the evidence that the T cells can recog-
Table I. Fresh CD1-WT–reactive Va14-Ja281 T Cells Respond Poorly To CD1-TD
No. of cells RBL.CD1-WT RBL.CD1-TD
3104 IL-4 (U/ml)
Va14 Tg thymocytes 5 975 32
(100% Va14) 1 306 22
1C8.DC1 5 240 320
(Va14-neg) 1 103 87
RBL.CD1-WT RBL.CD1-Phe
CD4 NK1.11 1 370 49
(81% Va14)
Va14 Tg thymocytes 1 130 5
(100% Va14)
CD4 NK1.12 1 695 400
(14% Va14)
1C8.DC1 1 120 85
(Va14-neg)
Thymocytes from Va14-Ja281 TCR a transgenic, Ca2/2 B6 mice or sorted CD41NK1.11 or CD41NK1.12 MHC II2/2 splenocytes (same as in
Fig. 1, containing an estimated frequency of 81 and 14% Va14-positive TCRs, respectively) were cultured for 5 d with 2.25 mg/ml Con A and IL-4
(10 ng/ml), washed, and restimulated for 20 h at indicated cell numbers with 104 RBL.CD1-WT, RBL.CD1-TD, or RBL.CD1-Phe cells express-
ing similar levels of surface CD1d, in the presence of 20 U/ml IL-2. IL-4 release was measured using the CT4.S bioassay. 1C8.DC1 is a control
Va14-negative CD1d-autoreactive hybridoma. Untransfected RBL cells elicited ,10 U/ml IL-4 in all cases. Results are representative of seven ex-
periments with Va14-Ja281 TCR a transgenic cells of either thymic or splenic origin, and of two experiments with sorted CD41NK1.11 or
CD41NK1.12 MHC II2/2 splenocytes. Tg, transgenic.
Figure 5. Both CD1d-restricted T cell
subsets contribute to the early burst of IL-4
and IFN-g induced by anti-CD3. RT-
PCR quantitation of cDNA (lower bands),
obtained from 105 FACS®-purified
CD41NK1.11 and CD41NK1.12 T cells
from MHC II2/2 mice injected 1.5 h ear-
lier, was performed against threefold dilu-
tions of competitor IL-4, IFN-g, and
HPRT plasmids (upper bands), as described in Materials and Methods. Results of two independent experiments, each with duplicate samples of 105
sorted cells, showed that both subsets contributed to the early cytokine release, although on a per cell basis the production of IL-4 and IFN-g by
CD41NK1.11 T cells was on average three- and twofold, respectively, above that of CD41NK1.12 T cells.109 Chiu et al.
nize both mouse and rat CD1-WT– and CD1-TD–trans-
fected cells indicates that the nature and the cellular distri-
bution of these self-antigens are conserved. An intriguing
possibility, suggested by current models of CD1/antigen/
TCR interactions (7, 36), is that the CD1d-restricted T
cells survey glycosylation changes in some conserved fami-
lies of glycolipids, and thus act as sentinels in various condi-
tions of stress, infection, or tumor growth where glycosyla-
tion processes may be affected. The finding that the
phenotypic properties of these cells are distributed accord-
ing to the antigens they recognize raises interesting devel-
opmental and functional issues.
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